IND-enabling studies expected to begin mid-2024WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taki
Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 9,630,000 shares, an increase of 6.2% from the February 29th total of 9,070,000 shares. Based on an average daily volume of 2,160,000 shares, […]
Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 9,630,000 shares, an increase of 6.2% from the February 29th total of 9,070,000 shares. Based on an average trading volume of 2,160,000 shares, […]
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Target Price at $13.67 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.